For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
16
references
 Top references
cited by
21
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      36
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus that can be fatal if left untreated. The causes and prognostic predictors of mortality in LN have been well studied in developed countries but evidence is lacking for developing countries. The objective of this study was to investigate the causes and predictors of mortality in a cohort of Malaysian patients with biopsy-proven LN.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.

          G Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron … (2010)
          Antimalarial drugs (AMs), chloroquine (CQ) and hydroxychloroquine (HCQ), are frequently withdrawn in patients with lupus with either severe or remitting disease. However, additional effects beyond immunomodulation have been recently described. The aim of the present work was to analyse all the published evidence of the beneficial and adverse effects of AM therapy in systemic lupus erythematosus (SLE). A systematic review of the English literature between 1982 and 2007 was conducted using the MEDLINE and EMBASE databases. Randomised controlled trials (RCTs) and observational studies were selected. Case reports were excluded except for toxicity reports. The GRADE system was used to analyse the quality of the evidence. A total of 95 articles were included in the systematic review. High levels of evidence were found that AMs prevent lupus flares and increase long-term survival of patients with SLE; moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss. Toxicity related to AMs is infrequent, mild and usually reversible, with HCQ having a safer profile. In pregnant women, high levels of evidence were found that AMs, particularly HCQ, decrease lupus activity without harming the baby. By contrast, evidence supporting an effect on severe lupus activity, lipid levels and subclinical atherosclerosis was weak. Individual papers suggest effects in preventing the evolution from SLE-like to full-blown SLE, influencing vitamin D levels and protecting patients with lupus against cancer. Given the broad spectrum of beneficial effects and the safety profile, HCQ should be given to most patients with SLE during the whole course of the disease, irrespective of its severity, and be continued during pregnancy.
          Article 0 comments Cited 237 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The frequency and outcome of lupus nephritis: results from an international inception cohort study.

            John G Hanly, Aidan O’Keeffe, Li Su … (2016)
            To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort.
            Article 0 comments Cited 170 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.

              J Sampalis, V Bykerk, JM Esdaile (1991)
              The antimalarial drug hydroxychloroquine is thought to be effective in controlling some of the manifestations of systemic lupus erythematosus, but its effectiveness has not been demonstrated conclusively. We conducted a six-month, randomized, double-blind, placebo-controlled study of the effect of discontinuing hydroxychloroquine sulfate treatment in 47 patients with clinically stable systemic lupus erythematosus. The patients were randomly assigned to continue their same dose of hydroxychloroquine (n = 25) or to receive placebo (n = 22) for 24 weeks. Ten patients in each group were also taking prednisone. The relative risk of a clinical flare-up, defined as the development of specific clinical manifestations of systemic lupus erythematosus or an increase in their severity, was 2.5 times higher (95 percent confidence interval, 1.08 to 5.58) in the patients taking placebo than in those continuing to take hydroxychloroquine (16 of 22 patients vs. 9 of 25 had flare-ups), and the time to a flare-up was shorter (P = 0.02). The relative risk of a severe exacerbation of disease that required withdrawal from the study was 6.1 times higher (95 percent confidence interval, 0.72 to 52.44) for the patients taking placebo (5 of 22 patients vs. 1 of 25 had severe exacerbations of disease). Changes in the dose of prednisone were not different in the two groups. Patients with quiescent systemic lupus erythematosus who are taking hydroxychloroquine are less likely to have a clinical flare-up if they are maintained on the drug.
              Article 0 comments Cited 145 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): Clin Kidney J
                Title: Clinical kidney journal
                Publisher: Oxford University Press (OUP)
                ISSN: 2048-8505
                ISSN (Print): 2048-8505
                Publication date (Electronic): Feb 2018
                Volume: 11
                Issue: 1
                Affiliations
                [1 ] Rheumatology Unit, Department of Medicine, Sarawak General Hospital, Sarawak, Malaysia.
                [2 ] Nephrology Unit, Department of Medicine, Sarawak General Hospital, Sarawak, Malaysia.
                [3 ] Rheumatology Unit, Department of Medicine, Sibu Hospital, Sarawak, Malaysia.
                Article
                Publisher Item ID: sfx063
                DOI: 10.1093/ckj/sfx063
                PMC ID: 5798016
                PubMed ID: 29423203
                SO-VID: d71a0ae5-997d-4e37-b0f8-de6d1fb36956
                History

                Keywords: dialysis,lupus nephritis,mortality,outcome,systemic lupus erythematosus
                Data availability:
                Keywords: dialysis, lupus nephritis, mortality, outcome, systemic lupus erythematosus

                Comments

                Comment on this article

                scite_

                Similar content36

                See all similar

                Cited by20

                See all cited by

                Most referenced authors434

                See all reference authors